Failure of thyroid hormone treatment to prevent inflammation-induced white matter injury in the immature brain

Schang, A, Van Steenwinckel, J, Chevenne, D, Alkmark, M, Hagberg, H, Gressens, P and Fleiss, B 2014, 'Failure of thyroid hormone treatment to prevent inflammation-induced white matter injury in the immature brain', Brain, Behavior, and Immunity, vol. 37, pp. 95-102.


Document type: Journal Article
Collection: Journal Articles

Title Failure of thyroid hormone treatment to prevent inflammation-induced white matter injury in the immature brain
Author(s) Schang, A
Van Steenwinckel, J
Chevenne, D
Alkmark, M
Hagberg, H
Gressens, P
Fleiss, B
Year 2014
Journal name Brain, Behavior, and Immunity
Volume number 37
Start page 95
End page 102
Total pages 8
Publisher Academic Press
Abstract Preterm birth is very strongly associated with maternal/foetal inflammation and leads to permanent neurological deficits. These deficits correlate with the severity of white matter injury, including maturational arrest of oligodendrocytes and hypomyelination. Preterm birth and exposure to inflammation causes hypothyroxinemia. As such, supplementation with thyroxine (T4) seems a good candidate therapy for reducing white matter damage in preterm infants as oligodendrocyte maturation and myelination is regulated by thyroid hormones. We report on a model of preterm inflammation-induced white matter damage, in which induction of systemic inflammation by exposure from P1 to P5 to interleukin-1β (IL-1β) causes oligodendrocyte maturational arrest and hypomyelination. This model identified transient hypothyroidism and wide-ranging dysfunction in thyroid hormone signalling pathways. To test whether a clinically relevant dose of T4 could reduce inflammation-induced white matter damage we concurrently treated mice exposed to IL-1β from P1 to P5 with T4 (20 μg/kg/day). At P10, we isolated O4-positive pre-oligodendrocytes and gene expression analysis revealed that T4 treatment did not recover the IL-1β-induced blockade of oligodendrocyte maturation. Moreover, at P10 and P30 immunohistochemistry for markers of oligodendrocyte lineage (NG2, PDGFRα and APC) and myelin (MBP) similarly indicated that T4 treatment did not recover IL-1β-induced deficits in the white matter. In summary, in this model of preterm inflammation-induced white matter injury, a clinical dose of T4 had no therapeutic efficacy. We suggest that additional pre-clinical trials with T4 covering the breadth and scope of causes and outcomes of perinatal brain injury are required before we can correctly evaluate clinical trials data and understand the potential for thyroid hormone as a widely implementable clinical therapy.
Subject Neurology and Neuromuscular Diseases
Paediatrics
Cell Physiology
Keyword(s) Myelination
Neuroprotection
Oligodendrocyte
Prematurity
Thyroxine
DOI - identifier 10.1016/j.bbi.2013.11.005
Copyright notice © 013 The Authors.
ISSN 0889-1591
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 19 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 1 Abstract Views  -  Detailed Statistics
Created: Thu, 31 Jan 2019, 11:26:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us